Amantadine ER Curbs Levodopa-Induced Dyskinesia in PDAmantadine ER Curbs Levodopa-Induced Dyskinesia in PD

An investigational extended-release formulation of amantadine with a unique chronotherapeutic pharmacokinetic profile eases levodopa-induced dyskinesia in a phase 2/3 study. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Publication date: Available online 15 August 2018Source: Neuroscience LettersAuthor(s): Justin Y. Lu, Arun K. Tiwari, Gwyneth C. Zai, Anjali Rastogi, Sajid A. Shaikh, Daniel J. Mueller, Aristotle N. Voineskos, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Gary Remington, Albert H.C. Wong, James L. Kennedy, Clement C. ZaiAbstractTardive dyskinesia (TD) is an involuntary movement disorder that occurs in ~20% of patients after extended antipsychotic use. Its pathophysiology is unclear; however, familial patterns and gene association studies indicate an inherited component to risk. The disrupted in schizophrenia ...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
ConclusionThese results show that the increase of SERT radioligand binding is not systematically paralleled by an increase of SERT fibers and does not always reflect the presence of LID. More specifically, our study suggest that SERT increase may be underpinned by an increased density of serotonergic fibers after MPTP and the first L-DOPA period, and by an elevation of SERT itself after MDMA and the second L-DOPA period. This highlights that DTI is complementary to PET imaging to decipher pathophysiological mechanisms underlying L-DOPA-induced dyskinesia in a non-human primate model of PD.
Source: NeuroImage - Category: Neuroscience Source Type: research
CONCLUSIONS In the present study, which marks the first Phase I pilot study of unilateral MRgFUS pallidotomy for parkinsonian dyskinesia, the authors demonstrated the efficacy of pallidal lesioning using MRgFUS and certain limitations that are unavoidably associated with incomplete thermal lesioning due to technical issues. Further investigation and long-term follow-up are necessary to validate the use of MRgFUS in clinical practice. Clinical trial registration no.: NCT02003248 ( PMID: 30095337 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
We present a summary of structural findings that have been described in PCD and highlight the radiological differences between PCD and other causes of bronchiectasis. We suggest that a PCD specific CT scoring system is required to properly describe changes seen in PCD.
Source: Multidisciplinary Respiratory Medicine - Category: Respiratory Medicine Source Type: research
We describe the main PCD diagnostic tests and compare the two international PCD diagnostic guidelines. The expensive multi-test diagnostic approach requiring a high level of expertise and specialist equipment, make the multifaceted PCD diagnostic pathway complex. Therefore, the risk of late or missed diagnosis is high and has clinical and research implications.Defining the number of patients with bronchiectasis due to PCD is complex. To date, few studies outlining the aetiology of adult patients with bronchiectasis conduct screening tests for PCD, but they do differ in their diagnostic approach. Comparison of these studies...
Source: Multidisciplinary Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Abstract N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors that mediate excitatory neurotransmission in the mammalian central nervous system (CNS), and their dysregulation results in the aetiology of many CNS syndromes. Several NMDAR modulators have been used successfully in clinical trials (including memantine) and NMDARs remain a promising pharmacological target for the treatment of CNS syndromes. 1,2,3,4-Tetrahydro-9-aminoacridine (tacrine; THA) was the first approved drug for Alzheimer's disease (AD) treatment. 7-methoxyderivative of THA (7-MEOTA) is less toxic and showed promising res...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Neuropharmacology Source Type: research
AbstractAmantadine extended-release (ER) capsules (GOCOVRI™) are approved in the USA for the treatment of dyskinesia in patients with Parkinson ’s disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications. With a recommended dosage of 274 mg once daily at bedtime, this new formulation of amantadine allows a more gradual time to peak plasma amantadine concentration and higher drug concentrations i n the morning and throughout the day, the time period when levodopa-induced dyskinesia (LID) is the most problematic. In 13-week (EASE LID 3) and 25-week (EASE LID), ...
Source: CNS Drugs - Category: Neurology Source Type: research
CONCLUSIONS: The results failed to clearly support a contribution of the studied polymorphisms; this may be related to a dominant relationship with the disease duration confounding the effect on the prevalence of LID. PMID: 30075828 [PubMed - in process]
Source: Journal of Pharmacy and Pharmaceutical Sciences - Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research
This article is part of the Special Issue "Individualized Epilepsy Management: Medicines, Surgery and Beyond".
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
CONCLUSIONS: Participants with IDA/MTD/CA defects, which included individuals with CCDC39 or CCDC40 mutations, had worse lung function and growth indices compared to those with ODA defects and DNAH5 mutations, respectively. The only group with a significant lung function decline over time were participants with IDA/MTD/CA defects. PMID: 30067075 [PubMed - as supplied by publisher]
Source: Am J Respir Crit Car... - Category: Intensive Care Authors: Tags: Am J Respir Crit Care Med Source Type: research
More News: Amantadine | Brain | Carbidopa/Levodopa | Dyskinesia | Health | Neurology | Neurosurgery | Study | Symmetrel